This review highlights the evidence-based data to support current best management
practices for patients with recurrent and/or metastatic (R/M) head and neck squamous cell …

Over 90% of head and neck cancers overexpress the epidermal growth factor receptor
(EGFR). In diverse tumor types, EGFR overexpression has been associated with poorer …

Metastases remain the major cause of death from cancer. Recent molecular advances have
highlighted the importance of metabolic alterations in cancer cells, including the Warburg …

Anticancer drug nephrotoxicity is an important and increasing adverse drug event that limits
the efficacy of cancer treatment. The kidney is an important elimination pathway for many …

Head and neck cancers (HNC) represent the seventh most frequent cancer worldwide, with
squamous cell carcinomas as the most frequent histologic subtype. Standard treatment for …

Overexpression of the epidermal growth factor receptor (EGFR) is a common characteristic
of head and neck squamous cell carcinomas (HNSCC). Cetuximab is a chimeric anti-EGFR …

Purpose This multicenter phase III study evaluated the efficacy and safety of lapatinib, an
epidermal growth factor receptor/ErbB2 inhibitor, administered concomitantly with …

Novel targeted anti-cancer therapies have resulted in improvement in patient survival
compared to standard chemotherapy. Renal toxicities of targeted agents are increasingly …

Simple Summary Next-generation sequencing of head and neck squamous cell carcinoma
has revealed multiple new gene mutations, while simultaneously confirming the role of …

The majority of patients with head and neck squamous cell carcinoma (HNSCC) present
with advanced-stage disease. The current standard of care is surgery followed by adjuvant …